Irinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination
暂无分享,去创建一个
E. Papalambros | N. Tsavaris | C. Kosmas | A. Polyzos | G. Papastratis | A. Giannopoulos | M. Vadiaka | C. Koufos | A. Macheras | A. Dimitrakopoulos | H. Margaris | K. Gennatas | H. Tsipras
[1] Christian Jacques,et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.
[2] R. Labianca,et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.
[3] T. Chou,et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Pignon,et al. Prognostic value of neural invasion in rectal carcinoma: a multivariate analysis on 339 patients with curative resection. , 1995, European journal of cancer.
[5] M. Ratain,et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. , 1994, Cancer research.
[6] L. Liu,et al. DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. , 1989, Science.
[7] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[8] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[9] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.